Sign in
CompletedPhase 1

Psilocybin for Treatment of Obsessive Compulsive Disorder

Key facts

Who runs it
University of Arizona
Where
Tucson, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 1
People taking part
15 people enrolled
Started
2 Jan 2019
Ended
30 Dec 2023
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Psilocybin 100 mcg/kg
  • Psilocybin 300 mcg/kg
  • Lorazepam 1 mg
Record updated
30 August 2024

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Have moderate to severe OCD (DSM-5) after diagnostic interview using the Structured Clinical Interview for DSM-5 Research Version (SCID-R)
  • Failed at least one adequate attempted routine care treatment
  • Considered safe for independent living

Who cannot take part

  • Concurrent psychosis, active substance use disorder, or a personal history of psychosis
  • Subjects may not be using antidepressant medication for OCD for at least two weeks before receiving study drug, and they cannot require any sedative, narcotic, or neuroleptic medications on a regular basis. Any of these medications they have taken should have been stopped long enough in the past to allow for their elimination and safe withdrawal prior to starting administration of the study drug. The specific time required will be dependent on the medication the patient was previously receiving
  • Medical illness based on physical examination and routine blood testing that may complicate cardiovascular safety or drug metabolism or excretion, such as uncontrolled hypertension, severe cardiac disease, or kidney or liver failure
  • Unstable Chronic Obstructive Pulmonary Disease (COPD) or severe sleep apnea
  • Psychiatric comorbidity that may represent an acute risk to their own or others' safety
  • Allergy to lorazepam
  • Women who are pregnant, breastfeeding, or unwilling/unable to practice medically acceptable birth control during the study

Where in United States

  • University of ArizonaTucson, United States

About the trial

What the trial wants to find out

This study will evaluate whether psilocybin, a hallucinogenic drug, improves symptoms of obsessive compulsive disorder (OCD), whether it is safely tolerated as treatment of OCD, and will investigate the mechanisms by which it works.

The 3 groups in the trial

  • High-dose PsilocybinTreatment being tested

    Psilocybin 300 mcg/kg once per week, every week, for 8 weeks

    Treatment: Psilocybin 300 mcg/kg

  • High- or Low-dose PsilocybinTreatment being tested

    Psilocybin 100 mcg/kg or psilocybin 300 mcg/kg once per week, every week, for 8 weeks

    Treatment: Psilocybin 100 mcg/kg and Psilocybin 300 mcg/kg

  • High-dose Psilocybin or LorazepamPlacebo, for comparison

    Psilocybin 300 mcg/kg or Lorazepam 1 mg once per week, every week, for 8 weeks

    Treatment: Psilocybin 300 mcg/kg and Lorazepam 1 mg

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
30 August 2024